Given that these reports and the four cases of long-term response to immunotherapy (> 2 years) had good PS in our study, if treatment with ICIs is planned for EGFR-mutant lung cancer, it should be considered at least in patients who have maintained a good PS (0–1). This evidence concerns the gene EGFR and lung carcinoma.